Outcomes of Patients with Gastrointestinal Stromal Tumors in the Past Decade.
GI neurotransmitter
GISTs
SEER database
clinical characteristics
mortality
pacemaker
Journal
Medical sciences (Basel, Switzerland)
ISSN: 2076-3271
Titre abrégé: Med Sci (Basel)
Pays: Switzerland
ID NLM: 101629322
Informations de publication
Date de publication:
28 08 2023
28 08 2023
Historique:
received:
03
07
2023
revised:
10
08
2023
accepted:
25
08
2023
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the gastrointestinal tract (GIT) that represent approximately 1 to 2 percent of primary gastrointestinal (GI) cancers. Owing to their rarity, very little is known about their overall epidemiology, and the prognostic factors of their pathology. The current study aimed to evaluate the independent determinants of mortality in patients diagnosed with GISTs over the past decade. Our study comprised 2374 patients diagnosed with GISTs from 2000 to 2017 from the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed the baseline characteristics, and overall mortality (OM), as well as the cancer-specific mortality (CSM) of GISTs. Variables with a Multivariate Cox proportional hazard regression analyses of factors affecting the all-cause mortality and GIST-related mortality among US patients between 2010 and 2017 revealed a higher overall mortality in non-Hispanic Black patients (HR = 1.516, 95% CI 1.172-1.961, In this updated study on the outcomes of patients with GISTs, we found that non-Hispanic Black patients, male patients, and patients older than 60 years have a higher mortality with GISTs. Furthermore, patients who have received chemotherapy have a higher GIST-specific mortality, and married patients have a lower mortality. However, we do not know to what extent these independent prognostic factors interact with each other to influence mortality. This study paves the way for future studies addressing these interactions. The results of this study may help treating clinicians to identify patient populations associated with a dismal prognosis, as those may require closer follow-up and more intensive therapy; furthermore, with married patients having a better survival rate, we hope to encourage clinicians to involve family members of the affected patients early in the disease course, as the social support might impact the prognosis.
Sections du résumé
BACKGROUND
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the gastrointestinal tract (GIT) that represent approximately 1 to 2 percent of primary gastrointestinal (GI) cancers. Owing to their rarity, very little is known about their overall epidemiology, and the prognostic factors of their pathology. The current study aimed to evaluate the independent determinants of mortality in patients diagnosed with GISTs over the past decade.
METHODS
Our study comprised 2374 patients diagnosed with GISTs from 2000 to 2017 from the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed the baseline characteristics, and overall mortality (OM), as well as the cancer-specific mortality (CSM) of GISTs. Variables with a
RESULTS
Multivariate Cox proportional hazard regression analyses of factors affecting the all-cause mortality and GIST-related mortality among US patients between 2010 and 2017 revealed a higher overall mortality in non-Hispanic Black patients (HR = 1.516, 95% CI 1.172-1.961,
CONCLUSION
In this updated study on the outcomes of patients with GISTs, we found that non-Hispanic Black patients, male patients, and patients older than 60 years have a higher mortality with GISTs. Furthermore, patients who have received chemotherapy have a higher GIST-specific mortality, and married patients have a lower mortality. However, we do not know to what extent these independent prognostic factors interact with each other to influence mortality. This study paves the way for future studies addressing these interactions. The results of this study may help treating clinicians to identify patient populations associated with a dismal prognosis, as those may require closer follow-up and more intensive therapy; furthermore, with married patients having a better survival rate, we hope to encourage clinicians to involve family members of the affected patients early in the disease course, as the social support might impact the prognosis.
Identifiants
pubmed: 37755158
pii: medsci11030054
doi: 10.3390/medsci11030054
pmc: PMC10536810
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Palliat Med. 2021 Mar;10(3):2990-2999
pubmed: 33615813
BMC Cancer. 2015 Jul 30;15:557
pubmed: 26223313
J Racial Ethn Health Disparities. 2019 Oct;6(5):1035-1043
pubmed: 31215017
J Surg Oncol. 2008 Oct 1;98(5):384-92
pubmed: 18668671
Semin Diagn Pathol. 2006 May;23(2):70-83
pubmed: 17193820
Int J Cancer. 2005 Nov 1;117(2):289-93
pubmed: 15900576
Sci Rep. 2021 Apr 21;11(1):8603
pubmed: 33883627
Ann Surg. 2021 Jan 1;273(1):128-138
pubmed: 30946076
AJR Am J Roentgenol. 2006 Nov;187(5):1267-73
pubmed: 17056915
Lancet. 2009 Mar 28;373(9669):1097-104
pubmed: 19303137
Breast. 2017 Apr;32:13-17
pubmed: 28012410
J Surg Oncol. 2015 May;111(6):696-701
pubmed: 25560251
Obes Surg. 2014 Dec;24(12):2134-7
pubmed: 24965544
Int J Colorectal Dis. 2018 Aug;33(8):1001-1010
pubmed: 29546559
Cancer Control. 2021 Jan-Dec;28:10732748211066309
pubmed: 34910613
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):298-302
pubmed: 25277795
Hum Pathol. 2006 Dec;37(12):1527-35
pubmed: 16996566
Cancer Med. 2018 Aug;7(8):3722-3742
pubmed: 30009575
Am J Surg Pathol. 2007 Jan;31(1):113-20
pubmed: 17197927
Hum Pathol. 1999 Oct;30(10):1213-20
pubmed: 10534170
J Am Coll Surg. 2009 Jul;209(1):7-16
pubmed: 19651058
Rev Esp Enferm Dig. 2020 Feb;112(2):109-117
pubmed: 31830797
Future Oncol. 2019 Dec;15(34):3963-3976
pubmed: 31746633
Cancers (Basel). 2022 Jul 28;14(15):
pubmed: 35954353
Cancer. 2005 Feb 15;103(4):821-9
pubmed: 15648083
J Comput Assist Tomogr. 2003 Sep-Oct;27(5):792-8
pubmed: 14501372
Br J Surg. 2006 Jul;93(7):836-43
pubmed: 16705644
BMC Cancer. 2021 Aug 5;21(1):891
pubmed: 34353300
Virchows Arch. 2001 Jan;438(1):1-12
pubmed: 11213830
Cancer Epidemiol. 2016 Feb;40:39-46
pubmed: 26618334
Ann Surg Oncol. 2013 Dec;20(13):4212-8
pubmed: 24052319
Int J Surg Pathol. 2002 Apr;10(2):81-9
pubmed: 12075401
BMC Cancer. 2007 Dec 20;7:230
pubmed: 18096058
J Am Coll Surg. 2006 Apr;202(4):623-9
pubmed: 16571433
ESMO Open. 2022 Dec;7(6):100649
pubmed: 36493601
Lancet. 2013 Sep 14;382(9896):973-83
pubmed: 23623056
World J Surg Oncol. 2011 Feb 01;9:13
pubmed: 21284869
Am J Surg Pathol. 2016 Dec;40(12):e94-e102
pubmed: 27740970
Hematology. 2022 Dec;27(1):187-197
pubmed: 35068385
Am J Gastroenterol. 2005 Jan;100(1):162-8
pubmed: 15654796